A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
SOLVONIS THERAPEUTICS PLC ORD G operates in the Industrial - Machinery industry, Industrials sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | - | - |
| Net Income | -2.0M | -2.0M | -3.9M | -3.3M |
| EPS | $0.00 | - | - | - |
| Free Cash Flow | -1.4M | -1.4M | -1.8M | -3.8M |
| ROIC | - | - | -97.6% | -74.6% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.00 | - | 0.01 | 0.00 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -1.8M | -1.8M | -3.9M | -3.3M |
| Operating Margin | 0.0% | - | - | - |
| ROE | 0.0% | - | -95.7% | -59.4% |
| Shares Outstanding | 0M | - | - | - |
| Metric | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | N/A | N/A | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A |
| EBIT | -3.3M | -3.9M | -1.8M | -1.8M |
| Op. Margin | N/A | N/A | N/A | 0.0% |
| Net Income | -3.3M | -3.9M | -2.0M | -2.0M |
| Net Margin | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | -74.6% | -97.6% | N/A | N/A |
| ROE | -59.4% | -95.7% | N/A | 0.0% |
| ROA | -54.8% | -85.3% | -57.0% | -49.6% |
| Cash Flow | ||||
| Op. Cash Flow | -2.9M | -1.5M | -1.4M | -1.4M |
| Free Cash Flow | -3.8M | -1.8M | -1.4M | -1.4M |
| Owner Earnings | -4.1M | -2.2M | -1.9M | -1.9M |
| CapEx | 885K | 270K | 0 | 0 |
| Maint. CapEx | 139K | 223K | 0 | 0 |
| Growth CapEx | 746K | 46K | N/A | 0 |
| D&A | 139K | 223K | 0 | 0 |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 1.1M | 461K | 406K | 406K |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | -2.0M | -166K | -968K | -968K |
| Cash & Equiv. | 2.0M | 193K | 968K | 968K |
| Long-Term Debt | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.00 | 0.01 | N/A | 0.00 |
| Interest Coverage | -675.2 | -1039.0 | -21.6 | -21.6 |
| Equity | 5.6M | 2.5M | N/A | 0 |
| Total Assets | 6.1M | 3.0M | 4.1M | 4.1M |
| Total Liabilities | 475K | 509K | N/A | N/A |
| Intangibles | N/A | 2.6M | 2.7M | 2.7M |
| Retained Earnings | -7.2M | -11M | -14M | -14M |
| Working Capital | 2.2M | -90K | 890K | 890K |
| Current Assets | 2.7M | 392K | 1.0M | 1.0M |
| Current Liabilities | 452K | 482K | 152K | 152K |
| Per Share Data | ||||
| EPS | N/A | N/A | N/A | 0.00 |
| Owner EPS | N/A | N/A | N/A | N/A |
| Book Value | N/A | N/A | N/A | 0.00 |
| Cash Flow/Share | N/A | N/A | N/A | 0.00 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | N/A | N/A | N/A | 0.0M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | N/A |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | N/A |
| Market Cap | 0 | 0 | 0 | 0 |
| Avg. Price | 20.40 | 6.36 | 0.39 | 0.26 |
| Year-End Price | 16.82 | 0.92 | 0.27 | 0.26 |
SOLVONIS THERAPEUTICS PLC ORD G passes 0 of 9 quality checks, indicating weak fundamentals.
SOLVONIS THERAPEUTICS PLC ORD G (SVNS-L) has a 5-year average return on invested capital (ROIC) of -86.1%. This is below average and may indicate limited pricing power.
SOLVONIS THERAPEUTICS PLC ORD G (SVNS-L) does not currently pay a regular dividend.
SOLVONIS THERAPEUTICS PLC ORD G (SVNS-L) operates in the Industrial - Machinery industry, within the Industrials sector.
SOLVONIS THERAPEUTICS PLC ORD G (SVNS-L) generated $-1 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
The Ledger Terminal provides 3 years of financial data for SOLVONIS THERAPEUTICS PLC ORD G (SVNS-L), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
No recent press releases.